Search results for "Original Articles: Thrombosis"

showing 3 items of 3 documents

Evaluation of the predictive value of the bleeding prediction score VTE‐BLEED for recurrent venous thromboembolism

2019

Abstract Introduction VTE‐BLEED is a validated score for identification of patients at increased risk of major bleeding during extended anticoagulation for venous thromboembolism (VTE). It is unknown whether VTE‐BLEED high‐risk patients also have an increased risk for recurrent VTE, which would limit the potential usefulness of the score. Methods This was a post hoc analysis of the randomized, double‐blind, placebo‐controlled PADIS‐PE trial that randomized patients with a first unprovoked pulmonary embolism (PE) initially treated during 6 months to receive an additional 18‐month of warfarin vs. placebo. The primary outcome of this analysis was recurrent VTE during 2‐year follow‐up after ant…

medicine.medical_specialtyrecurrencemedicine.drug_classvenous thromboembolismInternal medicinemedicineCumulative incidencecardiovascular diseasesanticoagulation therapylcsh:RC633-647.5business.industryAnticoagulantHazard ratioWarfarinlcsh:Diseases of the blood and blood-forming organsprediction scoreHematologyBleedbleedingequipment and suppliesmedicine.diseaseConfidence intervalPulmonary embolismDiscontinuationOriginal ArticlebusinessOriginal Articles: Thrombosismedicine.drugResearch and Practice in Thrombosis and Haemostasis
researchProduct

Global public awareness about atrial fibrillation

2017

Essentials Early recognition of atrial fibrillation helps in stroke prevention. Survey in 10 countries to assess public awareness of atrial fibrillation. Overall global awareness of atrial fibrillation was 48%. Less than 46% of participants were aware atrial fibrillation leads to stroke. Background Atrial fibrillation (AF) is an important cause of ischemic stroke that often remains undetected until stroke occurs. Awareness of the risk factors and symptoms is important so that AF can be diagnosed and thromboprophylaxis given. However, the extent of public awareness of AF is uncertain. We assessed public awareness of AF across six continents and compared it with that of other thrombotic and n…

medicine.medical_specialtyDeep veinPopulationpopulation030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinepreventionInternal medicinePalpitationsmedicineatrial fibrillationawarenesssurvey030212 general & internal medicineeducationStrokethrombosisPublic awarenesseducation.field_of_studybusiness.industryAtrial fibrillationHematologyglobalmedicine.diseaseThrombosisConfidence intervalmedicine.anatomical_structureinternationalEmergency medicineCardiologyOriginal Articlemedicine.symptombusinessOriginal Articles: ThrombosisResearch and Practice in Thrombosis and Haemostasis
researchProduct

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

2018

Abstract Background Prediction models for venous thromboembolism recurrence will likely be improved by adding levels of coagulation factors. Risk assessment is ideally performed during anticoagulant treatment, however, the influence of direct oral anticoagulants on coagulation factors is uncertain. Objective To assess the influence of rivaroxaban and apixaban on several coagulation factor levels. Methods In two crossover trials we assessed the influence of rivaroxaban and apixaban intake on factor (F)VIII, FXI and FXII‐activity and fibrinogen, von Willebrand factor (VWF:Ag), and d‐dimer levels. At three sessions with a washout period in between, blood was taken from 12 healthy male individu…

medicine.medical_specialtymedicine.drug_mechanism_of_actionFactor Xa Inhibitorapixabanfactor Xa inhibitors030204 cardiovascular system & hematologyTreatment resultsFibrinogenGastroenterology03 medical and health sciences0302 clinical medicineVon Willebrand factorInternal medicinecoagulantsMedicinerivaroxabanBlood coagulation testRivaroxabanbiologybusiness.industryBrief Reportblood coagulation testsrisk assessmentHematologyCoagulation030220 oncology & carcinogenesisbiology.proteinApixabanbusinessOriginal Articles: Thrombosismedicine.drug
researchProduct